Login
$VANI
$1.02 +$0.01 (0.99%) Live

$VANI SEC Filings

Filed On Filing
16 Nov 2026 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

16 Nov 2026 Form 4: Williams Gregg, Director

Bought 48,100 shares ($47.8K)

13 Nov 2026 Form 4: Dwyer Donald, Chief Business Officer

Bought 20,000 shares ($19.6K)

12 Nov 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more

Top-line results for SLIM-1™, the first-in-human Phase 1 trial of NPM-139, Vivani's miniature, ultra-long-acting semaglutide implant under development for chronic weight management, are anticipated for announcement later this week

12 Nov 2026 10-Q
30 Oct 2026 8-K: Regulation FD Disclosure

As previously disclosed, Vivani Medical, Inc. (“Vivani”) entered into a definitive agreement and plan of merger among its wholly owned subsidiary Cortigent, Inc. (“Cortigent”), ClearOne, Inc. (“ClearOne”), and CLRO Merger Sub, Inc. (“Mer...

29 Oct 2026 8-K: Regulation FD Disclosure

Vivani Medical, Inc. (“Vivani”) from time to time presents, and/or distributes to the investment community at various industry and other conferences, slide presentations to provide updates and summaries of its business. A copy of these s...

19 Oct 2026 Form 4: Mendelsohn Aaron, Director

Gave 20,000 shares as a gift

25 Sep 2026 424B5
16 Sep 2026 8-K: Regulation FD Disclosure

As previously disclosed, Vivani Medical, Inc. (“Vivani”) entered into a definitive agreement and plan of merger among its wholly owned subsidiary Cortigent, Inc. (“Cortigent”), ClearOne, Inc. (“ClearOne”), and CLRO Merger Sub, Inc. (“Mer...

17 Aug 2026 8-K: Regulation FD Disclosure

Vivani Medical, Inc. (“Vivani”) from time to time presents, and/or distributes to the investment community at various industry and other conferences, slide presentations to provide updates and summaries of its business. A copy of these s...

13 Aug 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

All participants successfully dosed in SLIM-1™, the Company's first-in-human Phase 1 trial of NPM-139, a miniature, ultra long-acting semaglutide implant for chronic weight management; top-line data expected in November 2026

13 Aug 2026 10-Q
06 Aug 2026 8-K: Regulation FD Disclosure

Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management

30 Jul 2026 Form 4: Dwyer Donald, Chief Business Officer

Granted 70,000 Common Stock Option · Granted 35,000 RSUs

30 Jul 2026 Form 4: Porter Lisa Ellen, Chief Medical Officer

Granted 80,000 Common Stock Option · Granted 40,000 RSUs

30 Jul 2026 Form 4: Baldor Anthony, Chief Financial Officer

Granted 75,000 Common Stock Option · Granted 37,500 RSUs

30 Jul 2026 Form 4: Le Truc, Chief Operations Officer

Granted 160,000 Common Stock Option · Granted 80,000 RSUs

30 Jul 2026 Form 4: Mendelsohn Adam, Director

Granted 200,000 Common Stock Option · Granted 100,000 RSUs

28 Jul 2026 Form 4: Bradbury Daniel, Director

Granted 7,965 Non-Qualified Stock Option (right to buy) ($10.4K)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support